In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrbusNeich: Tissue Engineering Meets Coronary Stents

Executive Summary

While most companies are developing new ways to deliver drugs off of stents, OrbusNeich is looking to capture circulating endothelial progenitor cells onto its device to promote healing naturally, without drugs.

You may also be interested in...



EuroPCR Highlights: TAVI Set to Continue Rampant Growth

With innovation as the theme of this year's EuroPCR meeting, emerging technology sessions and innovation presentations sparked lively discussions. While drug-eluting stents remained a key interest area, transcatheter aortic heart valve implantation sessions drew the largest crowds.

Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market

Which kinds of innovations make for incremental enhancements in the hands of large companies and which are meaningful enough to sustain a venture-backed start-up company? In a mature market for coronary stents dominated by large companies, start-ups developing new stents need to find the answers. Areas of innovation fall into four basic categories: improving stent safety and biocompatibility, avoiding the need for dual antiplatelet therapy, enhancing deliverability, and introducing specialty stents for complex vessels. Three companies profiled here have a plan for taking sufficient market share, reducing risk, and rewarding investors.

The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs

Growth by innovation is almost considered a birthright in interventional cardiology, and based on presentations at this year's Transcatheter Cardiovascular Therapeutics meeting, held this September in San Francisco, it seems clear that innovation still reigns supreme in this specialty. However, as in other medical device markets, ongoing economic and regulatory pressures are taking their toll, particularly in the drug-eluting stent market, as the field adjusts to a new era of cost control and economic uncertainty.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel